Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer

References

• Provine NM, Klenerman P. MAIT cells in health and disease. Annu Rev Immunol. 2020;38(1):203–8. doi: 10.1146/annurev-immunol-080719-015428.
   PubMedGoogle Scholar
• Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491(7426):717–723. doi: 10.1038/nature11605.
   PubMed Web of Science ®Google Scholar
• O’Neill C, Cassidy FC, O’Shea D, Hogan AE. Mucosal associated invariant T cells in cancer-friend or foe? Cancers Basel. 2021;13(7):1582. doi: 10.3390/cancers13071582.
   PubMed Web of Science ®Google Scholar
• Dias J, Boulouis C, Sobkowiak MJ, Lal KG, Emgard J, Buggert M, Parrot T, Gorin JB, Leeansyah E, Sandberg JK. Factors Influencing Functional Heterogeneity in Human Mucosa-Associated Invariant T Cells. Front Immunol. 2018;9:1602. doi: 10.3389/fimmu.2018.01602.
   PubMed Web of Science ®Google Scholar
• Yan J, Allen S, McDonald E, Das I, Mak JYW, Liu L, Fairlie DP, Meehan BS, Chen Z, Corbett AJ, et al. MAIT cells promote tumor initiation, growth, and metastases via tumor MR1. Cancer Discov. 2020;10(1):124–141. doi: 10.1158/2159-8290.CD-19-0569.
   PubMed Web of Science ®Google Scholar
• Petley EV, Koay HF, Henderson MA, Sek K, Todd KL, Keam SP, Lai J, House IG, Li J, Zethoven M, et al. MAIT cells regulate NK cell-mediated tumor immunity. Nat Commun. 2021;12(1):4746. doi: 10.1038/s41467-021-25009-4.
   PubMed Web of Science ®Google Scholar
• Ruf B, Catania VV, Wabitsch S, Ma C, Diggs LP, Zhang Q, Heinrich B, Subramanyam V, Cui LL, Pouzolles M, et al. Activating mucosal-associated invariant T cells induces a broad antitumor response. Cancer Immunol Res. 2021;9(9):1024–1034. doi: 10.1158/2326-6066.CIR-20-0925.
   PubMed Web of Science ®Google Scholar
• McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37(1):457–495. doi: 10.1146/annurev-immunol-041015-055318.
   PubMed Web of Science ®Google Scholar
• Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652–1669. doi: 10.1016/j.cell.2023.03.006.
   PubMed Web of Science ®Google Scholar
• Yao T, Shooshtari P, Haeryfar SMM. Leveraging public single-cell and bulk transcriptomic datasets to delineate MAIT cell roles and phenotypic characteristics in human malignancies. Front Immunol. 2020;11:1691. doi: 10.3389/fimmu.2020.01691.
   PubMed Web of Science ®Google Scholar
• Li S, Simoni Y, Becht E, Loh CY, Li N, Lachance D, Koo SL, Lim TP, Tan EKW, Mathew R, et al. Human tumor-infiltrating MAIT cells display hallmarks of bacterial antigen recognition in colorectal cancer. Cell Rep Med. 2020;1(3):100039. doi: 10.1016/j.xcrm.2020.100039.
   PubMedGoogle Scholar
• Rodin W, Sundstrom P, Ahlmanner F, Szeponik L, Zajt KK, Wettergren Y, Bexe Lindskog E, Quiding Jarbrink M. Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients. Cancer Immunol Immunother. 2021;70(12):3461–3475. doi: 10.1007/s00262-021-02939-y.
   PubMed Web of Science ®Google Scholar
• De Biasi S, Gibellini L, Lo Tartaro D, Puccio S, Rabacchi C, Mazza EMC, Brummelman J, Williams B, Kaihara K, Forcato M, et al. Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nat Commun. 2021;12(1):1669. doi: 10.1038/s41467-021-21928-4.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152. doi: 10.1016/S1470-2045(17)30074-8.
   PubMed Web of Science ®Google Scholar
• Langenskiold C, Mellgren K, Abrahamsson J, Bemark M. Determination of blood cell subtype concentrations from frozen whole blood samples using TruCount beads. Cytometry B Clin Cytom. 2018;94(4):660–666. doi: 10.1002/cyto.b.21390.
   PubMed Web of Science ®Google Scholar
• Larsen M, Sauce D, Arnaud L, Fastenackels S, Appay V, Gorochov G, Hoshino Y. Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS One. 2012;7(7):e42403. doi: 10.1371/journal.pone.0042403.
   PubMed Web of Science ®Google Scholar
• Loh L, Gherardin NA, Sant S, Grzelak L, Crawford JC, Bird NL, Koay HF, van de Sandt CE, Moreira ML, Lappas M, et al. Human mucosal-associated invariant T cells in older individuals display expanded TCRalphabeta clonotypes with potent antimicrobial responses. J Immunol. 2020;204(5):1119–1133. doi: 10.4049/jimmunol.1900774.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. doi: 10.1038/s41467-018-05072-0.
   PubMed Web of Science ®Google Scholar
• Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2023;56(1):93–106.e6. doi: 10.1016/j.immuni.2022.12.001.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, Junger WG, Robson SC, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PloS Pathog. 2015;11(10):e1005177. doi: 10.1371/journal.ppat.1005177.
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–461. doi: 10.1038/s41591-019-0357-y.
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi: 10.1038/nature22079.
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993–4998. doi: 10.1073/pnas.1705327114.
   PubMed Web of Science ®Google Scholar
• Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee SH, Ahn JS, Cheon J, Min YJ, Park SH, et al. The first-week proliferative response of peripheral blood PD-1(+)CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors. Clin Cancer Res. 2019;25(7):2144–2154. doi: 10.1158/1078-0432.CCR-18-1449.
   PubMed Web of Science ®Google Scholar
• Kestens L, Vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, Hulstaert F, Bach BA. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS. 1992;6(8):793–797. doi: 10.1097/00002030-199208000-00004.
   PubMed Web of Science ®Google Scholar
• Chraa D, Naim A, Olive D, Badou A. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol. 2019;105(2):243–255. doi: 10.1002/JLB.MR0318-097R.
   PubMed Web of Science ®Google Scholar
• Ouyang L, Wu M, Zhao J, Jiang L, Shen Z, Cheng X, Wang W, Wu X, Cao X, Weng X. Mucosal-associated invariant T cells reduce and display tissue-resident phenotype with elevated IL-17 producing capacity in non-small cell lung cancer. Int Immunopharmacol. 2022;113(Pt B):109461. doi: 10.1016/j.intimp.2022.109461.
   PubMedGoogle Scholar
• Shi L, Lu J, Zhong D, Song M, Liu J, You W, Li WH, Lin L, Shi D, Chen Y. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy. J Immunother Cancer. 2023;11(1):e005902. doi: 10.1136/jitc-2022-005902.
   PubMed Web of Science ®Google Scholar
• Meierovics AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. J Exp Med. 2016;213(12):2793–2809. doi: 10.1084/jem.20160637.
   PubMed Web of Science ®Google Scholar
• Vorwald VM, Davis DM, Van Gulick RJ, Torphy RJ, Borgers JS, Klarquist J, Couts KL, Amato CM, Cogswell DT, Fujita M, et al. Circulating CD8(+) mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients. Clin Trans Immunol. 2022;11(1):e1367. doi: 10.1002/cti2.1367.
   PubMed Web of Science ®Google Scholar